gr 144053 has been researched along with mci 9038 in 2 studies
| Studies (gr 144053) | Trials (gr 144053) | Recent Studies (post-2010) (gr 144053) | Studies (mci 9038) | Trials (mci 9038) | Recent Studies (post-2010) (mci 9038) |
|---|---|---|---|---|---|
| 21 | 1 | 2 | 1,087 | 83 | 349 |
| Protein | Taxonomy | gr 144053 (IC50) | mci 9038 (IC50) |
|---|---|---|---|
| Prothrombin | Homo sapiens (human) | 0.22 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Collen, D; Kozawa, O; Matsuno, H; Matsuo, O; Uematsu, T; Ueshima, S | 1 |
| Kozawa, O; Matsuno, H; Matsuo, O; Okada, K; Uematsu, T; Ueshima, S | 1 |
2 other study(ies) available for gr 144053 and mci 9038
| Article | Year |
|---|---|
Lack of tPA significantly affects antithrombotic therapy by a GPIIb/IIIa antagonist, but not by a thrombin inhibitor in mice.
Topics: Animals; Arginine; Bleeding Time; Carotid Artery Thrombosis; Dose-Response Relationship, Drug; Fibrinolytic Agents; Mice; Mice, Knockout; Pipecolic Acids; Piperazines; Piperidines; Platelet Glycoprotein GPIIb-IIIa Complex; Sulfonamides; Thrombin; Thrombolytic Therapy; Tissue Plasminogen Activator; Urokinase-Type Plasminogen Activator | 2000 |
Inhibitors of fibrinolytic components play different roles in the formation and removal of arterial thrombus in mice.
Topics: alpha-2-Antiplasmin; Animals; Arginine; Bleeding Time; Blood Coagulation; Carotid Artery Injuries; Endothelium, Vascular; Mice; Mice, Inbred C57BL; Mice, Knockout; Pipecolic Acids; Piperazines; Piperidines; Plasminogen Activator Inhibitor 1; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Serine Proteinase Inhibitors; Sulfonamides; Thrombin; Thrombin Time; Thrombosis; Vascular Patency | 2002 |